A prospective study comparing short versus standard dual antiplatelet therapy in patients with acute myocardial infarction: design and rationale of the TARGET-FIRST trial
Study context
- Population
- Patients with NSTEMI/STEMI completely revascularised at index or staged procedure (within 7 days) with the Firehawk biodegradable polymer rapamycin-eluting stentplanned sample size
- Participants
- 2,246 patients
- Planned comparison
- Short dual antiplatelet therapy (DAPT) vs standard DAPT
- Primary endpoint
- Net adverse clinical and cerebral events (non-inferiority of short antiplatelet therapy)
Methodological detailsdesign and rationale, prospective, open-label, multicentre, non-inferiority, ≈50 sites in Europe, Main secondary endpoint, if primary met: superiority of short DAPT for major or clinically relevant non-major bleeding
- Design and rationale
- Prospective
- Open-label
- Multicentre
- Non-inferiority
- ≈50 sites in Europe
- Main secondary endpoint, if primary met: superiority of short DAPT for major or clinically relevant non-major bleeding
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
A prospective study comparing short versus standard dual antiplatelet therapy in patients with acute myocardial infarction: design and rationale of the TARGET-FIRST trial. EuroIntervention. Published 19 June 2023. doi:10.
Summarised from the published abstract; every number is checked against it